ViroPharma Announces Cinryzeman Data Presented at 2011 AAAAI Annual Meeting

ViroPharma Incorporated

today announced data presented in two poster presentations relating to Cinryze at the 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting, March 18 through 22, in San Francisco, CA. Cinryze is the first and only U.S. FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (

), a rare, debilitating and potentially fatal disease. Cinryze is currently available only in the United States, and is not approved in the U.S. to treat acute angioedema attacks, for children with HAE, or for pre-procedure administration.